KAI ANDREWS: Open Payments
NPI 1659848760 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$881 in 12 payments from 9 companies in 2025. Trend: 2023 $1,381 · 2024 $443 · 2025 $881
Food & beverage: $881
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $249 |
| Daiichi Sankyo Inc. | 2 | $154 |
| Kite Pharma, Inc. | 1 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $110 |
| Janssen Biotech, Inc. | 1 | $89 |
| Ipsen Biopharmaceuticals, Inc | 1 | $88 |
| Merck Sharp & Dohme LLC | 1 | $25 |
| Novartis Pharmaceuticals Corporation | 1 | $23 |
| PUMA BIOTECHNOLOGY, INC. | 1 | $21 |
Products named: DATROWAY, FRUZAQLA, RYBREVANT, Onivyde, Enhertu, KEYTRUDA, KISQALI, NERLYNX.
Industry payments across MD — which companies pay providers there.
